Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?

Last month, the company announced positive data from the ongoing phase I repeat dose SANRECO study on its pipeline candidate, divesiran (SLN124) for treating patients with polycythemia vera. Treatment with divesiran was generally well-tolerated and eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing. This might have driven the share price rally. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) s ...